Business

- The approval of Beyonttra in Brazil is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen…

- The approval of Beyonttra in Brazil is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen…

PALO ALTO, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio” or the "Company”), a biopharmaceutical company focused on…

The ATTR amyloidosis pipeline has expanded far beyond patisiran, with RNA interference, CRISPR gene editing, monoclonal antibodies, and next-generation stabilizers…

Transthyretin amyloidosis is driving intensive pharmaceutical IP activity across four mechanistically distinct modalities — RNAi silencing, small-molecule…

Anumana, a Massachusetts-based artificial intelligence (AI) company co-founded by nference and Mayo Clinic, has received U.S. Food and Drug Administration (FDA)…

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Anumana, Inc., a leader in cardiovascular AI, today announced U.S. Food and Drug Administration (FDA) clearance of its ECG-AI™…

The round was led by new investor Frazier Life Sciences, with participation from F-Prime, Qiming Venture Partners, SR One and founding investors Cambridge…

Alnylam Pharmaceuticals highlighted the early commercial success of AMVUTTRA (vutrisiran) for ATTR cardiomyopathy during a recent webinar. The company reported a…

AbstractAmyloidosis comprises a heterogeneous group of disorders marked by the extracellular deposition of insoluble protein fibrils, known as amyloids, which can…